Literature DB >> 8471184

Theophylline. Current thoughts on the risks and benefits of its use in asthma.

S S Nasser1, P J Rees.   

Abstract

Theophylline and its derivatives have been used in the treatment of asthma for over 50 years, but since the advent of more potent bronchodilators their use has become cloaked in controversy. Their continued existence results from their undoubted usefulness in severe acute asthma, nocturnal asthma, childhood asthma and moderate to severe chronic airflow limitation, and because of habitual use by physicians in other situations. The precise mechanism of action of theophylline remains uncertain. The role of phosphodiesterase inhibition and adenosine antagonism has been reviewed and the clinical significance of the anti-inflammatory action of theophylline discussed. Theophylline has unpredictable metabolism when first administered, and continued monitoring of drug concentrations is essential. Commonly encountered adverse effects may occur at therapeutic serum concentrations, frequently necessitating drug withdrawal. The overlapping therapeutic and toxic theophylline serum ranges can lead to life-threatening adverse effects at the upper end of the therapeutic range, especially in the elderly in whom special precaution is required.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471184     DOI: 10.2165/00002018-199308010-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  62 in total

1.  The effects of theophylline on beta 2-adrenoceptors on polymorphonuclear leukocytes of asthmatic children and juveniles. Increase in receptor density and prevention of agonist-induced down-regulation.

Authors:  J Otto; S Günther; R Urbanek
Journal:  Eur J Pediatr       Date:  1990-06       Impact factor: 3.183

2.  Xanthines as airway anti-inflammatory drugs.

Authors:  C G Persson; A B Draco
Journal:  J Allergy Clin Immunol       Date:  1988-03       Impact factor: 10.793

Review 3.  Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance.

Authors:  F E Hargreave; G Ryan; N C Thomson; P M O'Byrne; K Latimer; E F Juniper; J Dolovich
Journal:  J Allergy Clin Immunol       Date:  1981-11       Impact factor: 10.793

4.  Intraindividual variability in theophylline pharmacokinetics: statistical verification in 39 of 60 healthy young adults.

Authors:  R A Upton; J F Thiercelin; T W Guentert; S M Wallace; J R Powell; L Sansom; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

Review 5.  Effects of enprofylline and theophylline may show the role of adenosine.

Authors:  C G Persson; K E Andersson; G Kjellin
Journal:  Life Sci       Date:  1986-03-24       Impact factor: 5.037

6.  The mast cell and theophylline in asthma.

Authors:  S I Wasserman
Journal:  Am J Med       Date:  1985-12-20       Impact factor: 4.965

7.  Diurnal rhythm of asthma.

Authors:  T J Clark
Journal:  Chest       Date:  1987-06       Impact factor: 9.410

8.  Aminophylline improves diaphragmatic contractility.

Authors:  M Aubier; A De Troyer; M Sampson; P T Macklem; C Roussos
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

9.  Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not.

Authors:  J I Dutoit; C M Salome; A J Woolcock
Journal:  Am Rev Respir Dis       Date:  1987-11

10.  Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis.

Authors:  M Aubier; J Levy; C Clerici; F Neukirch; F Cabrières; D Herman
Journal:  Am Rev Respir Dis       Date:  1991-02
View more
  2 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Efficacy and safety of salmeterol in childhood asthma.

Authors:  W Lenney; S Pedersen; A L Boner; A Ebbutt; M M Jenkins
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.